quinazolines has been researched along with ARS-1620 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 5 (83.33) | 2.80 |
| Authors | Studies |
|---|---|
| Babbar, A; Brehmer, D; Chen, JH; Chen, Y; Darjania, L; Deng, X; Dhanak, D; Ely, T; Feng, J; Firdaus, SJ; Guo, X; Hansen, R; Hu-Lowe, D; Janes, MR; Kessler, LV; Kucharski, JM; Li, LS; Li, S; Liu, Y; Long, YO; Lorenzi, MV; Patricelli, MP; Peters, U; Ren, P; Thach, C; Wang, Y; Wu, T; Yao, Y; Yu, K; Zarieh, A; Zarrinkar, PP; Zhang, J | 1 |
| Chavan, S; Darville, L; Fang, B; Franzese, R; Haura, EB; Imbody, D; Izumi, V; Kinose, F; Koomen, JM; Rix, U; Solanki, HS; Stone, B; Welsh, EA | 1 |
| Erlanson, DA; Webster, KR | 1 |
| Fang, J; Huang, J; Li, Y; Liu, H; Wang, J; Wang, X; Ye, J; Zhang, D; Zhang, M; Zhang, X; Zhang, Z | 1 |
| Gammon, ST; Muzzioli, R; Pisaneschi, F; Piwnica-Worms, D; Radaram, B; Sutton, MN; Yang, P | 1 |
| Chen, J; Li, L; Liu, J; Mai, R; Zhao, H | 1 |
1 review(s) available for quinazolines and ARS-1620
| Article | Year |
|---|---|
Targeting mutant KRAS.
Topics: Acetonitriles; Animals; Antineoplastic Agents; Drug Design; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Mutant Proteins; Mutation; Piperazines; Precision Medicine; Protein Binding; Protein Conformation; Proto-Oncogene Proteins p21(ras); Pyridines; Pyrimidines; Quinazolines; Structure-Activity Relationship | 2021 |
5 other study(ies) available for quinazolines and ARS-1620
| Article | Year |
|---|---|
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Female; HCT116 Cells; HEK293 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Mutation; Neoplasms, Experimental; Piperazines; Protein Binding; Proto-Oncogene Proteins p21(ras); Quinazolines | 2018 |
Cell Type-specific Adaptive Signaling Responses to KRAS
Topics: Alleles; Amino Acid Substitution; Biomarkers, Tumor; Cell Line, Tumor; Chromatography, Liquid; Computational Biology; Epithelial-Mesenchymal Transition; Humans; Mutation; Phosphoproteins; Piperazines; Protein Interaction Mapping; Protein Interaction Maps; Proteomics; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Tandem Mass Spectrometry | 2021 |
Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant.
Topics: Animals; Cell Line, Tumor; Female; Fluorine Radioisotopes; Humans; Iodine Radioisotopes; Mice; Molecular Docking Simulation; Molecular Imaging; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiopharmaceuticals; Single Photon Emission Computed Tomography Computed Tomography; Tissue Distribution; Xenograft Model Antitumor Assays | 2021 |
RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging.
Topics: Albumins; Amiloride; Animals; Antineoplastic Agents; Cell Line, Tumor; Dextrans; Humans; Lung Neoplasms; Mice; Mutation; Optical Imaging; Pancreatic Neoplasms; Piperazines; Proto-Oncogene Proteins p21(ras); Quinazolines | 2022 |
Discovery of ARS-1620 analogs as KRas G12C inhibitors with high in vivo antitumor activity.
Topics: Animals; Guanosine Triphosphate; Humans; Mice; Mice, Nude; Mutation; Neoplasms; Piperazines; Proto-Oncogene Proteins p21(ras); Quinazolines | 2022 |